Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum-Reference-Cited by-同舟云学术

Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum

Published:2005-02 Issue:3 Volume:92 Page:433-441
ISSN:0022-3042
Container-title:Journal of Neurochemistry
language:en
Short-container-title:J Neurochem

Author:

Rodrigues Ricardo J.,Alfaro Tiago M.,Rebola Nelson,Oliveira Catarina R.,Cunha Rodrigo A.

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1471-4159.2004.02887.x/fullpdf

Reference32 articles.

1. Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity

2. G Protein–Coupled Receptor Oligomerization

3. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism

4. Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective

5. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adenosine and adenosine receptors in metabolic imbalance-related neurological issues;Biomedicine & Pharmacotherapy;2024-08

2. Adenosine A2A Receptor Blockade Provides More Effective Benefits at the Onset Rather than after Overt Neurodegeneration in a Rat Model of Parkinson’s Disease;International Journal of Molecular Sciences;2024-04-30

3. Striatal astrocytic A2A-D2 receptor-receptor interactions and their role in neuropsychiatric disorders;Neuropharmacology;2023-10

4. Striatopallidal adenosine A2A receptor modulation of goal-directed behavior: Homeostatic control with cognitive flexibility;Neuropharmacology;2023-03

5. Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence;Current Neuropharmacology;2023-03